Inion seals biomaterials R&D (research and development) pact with Cambridge Uni
This article was originally published in Clinica
Executive Summary
Inion, the Anglo-Finnish developer of biodegradable medical implants, is to collaborate with the University of Cambridge's Centre for Medical Materials (CCMM) over the next three years on the development of a new medical materials platform. This next-generation technology will combine Inion's Optima biodegradable polymers with nano-phase bioactive ceramics that are currently being developed by CCMM.
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.